It’s MCP projects in production, not specification elegance or market buzz, that will determine if MCP (or something else) stays on top.

Maack et al. [70] recently reported on switching between β blockers (metoprolol and carvedilol) in 68 patients treated with either agent for 1 year who had improved in terms of LVEF and NYHA class.